×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XERS – xeris biopharma holdings, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XERS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/11
01:43 pm
xers
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/6
06:11 am
xers
Xeris Biopharma (XERS) was upgraded by Weiss Ratings from "sell (d-)" to "hold (c-)".
Medium
Report
Xeris Biopharma (XERS) was upgraded by Weiss Ratings from "sell (d-)" to "hold (c-)".
3/4
07:43 am
xers
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio [Seeking Alpha]
Low
Report
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio [Seeking Alpha]
3/2
04:43 pm
xers
Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Low
Report
Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
3/2
12:53 pm
xers
Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/2
12:36 pm
xers
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
3/2
11:05 am
xers
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/2
07:19 am
xers
Xeris Biopharma: Q4 Earnings Snapshot [Yahoo! Finance]
High
Report
Xeris Biopharma: Q4 Earnings Snapshot [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
3/2/2026
07:00 am
XERS
xeris biopharma holdings, inc.
BEAT
Report
-5.9%
xeris biopharma holdings, inc.
11/6/2025
07:00 am
XERS
xeris biopharma holdings, inc.
MISS
Report
-15.3%
xeris biopharma holdings, inc.
8/7/2025
07:00 am
XERS
xeris biopharma holdings, inc.
BEAT
Report
20.0%
xeris biopharma holdings, inc.
5/8/2025
07:00 am
XERS
xeris biopharma holdings, inc.
BEAT
Report
17.3%
xeris biopharma holdings, inc.
Date
Time
Symbol
Headline
Impact
3/16
06:11 pm
xers
Form 4 Xeris Biopharma Holdings For: Mar 12 Filed by: McCulloch Kevin
Medium
Report
Form 4 Xeris Biopharma Holdings For: Mar 12 Filed by: McCulloch Kevin
3/5
07:18 pm
xers
Form 4 Xeris Biopharma Holdings For: Mar 05 Filed by: Pieper Steven
Medium
Report
Form 4 Xeris Biopharma Holdings For: Mar 05 Filed by: Pieper Steven
3/4
05:29 pm
xers
Form 4 Xeris Biopharma Holdings For: Mar 02 Filed by: Hecht Beth
Low
Report
Form 4 Xeris Biopharma Holdings For: Mar 02 Filed by: Hecht Beth
3/2
04:36 pm
xers
Form 144 Xeris Biopharma Holdings Filed by: Hecht Beth
Low
Report
Form 144 Xeris Biopharma Holdings Filed by: Hecht Beth
3/2
04:28 pm
xers
Form S-8 Xeris Biopharma Holdings
Low
Report
Form S-8 Xeris Biopharma Holdings
3/2
04:26 pm
xers
Form 10-K Xeris Biopharma Holdings For: Dec 31
Low
Report
Form 10-K Xeris Biopharma Holdings For: Dec 31
3/2
07:08 am
xers
Form 8-K Xeris Biopharma Holdings For: Mar 02
Medium
Report
Form 8-K Xeris Biopharma Holdings For: Mar 02
2/27
06:04 am
xers
Form 8-K Xeris Biopharma Holdings For: Feb 26
Medium
Report
Form 8-K Xeris Biopharma Holdings For: Feb 26
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Form S-8 XERIS PHARMACEUTICALS
28.5%
4/29 Xeris Extends $0 Copay for Gvoke™ PFS For People With Diabetes Through May 31, 2020 24.4%
3/16 Form 4 XERIS PHARMACEUTICALS For: Mar 13 Filed by: Hecht Beth 14.0%
1/6 Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise 9.4%
4/24 Form DEF 14A XERIS PHARMACEUTICALS For: Dec 31 9.0%
2/14 Form SC 13G XERIS PHARMACEUTICALS Filed by: ArrowMark Colorado Holdings LLC 8.3%
4/3 Xeris Pharmaceuticals Inc (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $18.00 price target on the stock. 8.1%
2/18 Form 4 XERIS PHARMACEUTICALS For: Feb 14 Filed by: Deutsch Barry M. 7.9%
6/17 Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon 7.6%
5/9 Q1/2019 3/31/2019 EPS -1.070 ZacksConsensus N/A ActVsEst N/A - N/A 7.6%
4/29 Xeris Extends $0 Copay for Gvoke™ PFS For People With Diabetes Through May 31, 2020 24.4%
3/16 Form 4 XERIS PHARMACEUTICALS For: Mar 13 Filed by: Hecht Beth 14.0%
1/6 Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise 9.4%
4/24 Form DEF 14A XERIS PHARMACEUTICALS For: Dec 31 9.0%
2/14 Form SC 13G XERIS PHARMACEUTICALS Filed by: ArrowMark Colorado Holdings LLC 8.3%
4/3 Xeris Pharmaceuticals Inc (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $18.00 price target on the stock. 8.1%
2/18 Form 4 XERIS PHARMACEUTICALS For: Feb 14 Filed by: Deutsch Barry M. 7.9%
6/17 Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon 7.6%
5/9 Q1/2019 3/31/2019 EPS -1.070 ZacksConsensus N/A ActVsEst N/A - N/A 7.6%
TOP News Decliners
2/10
Xeris Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of Common Stock
-29.1%
3/11 Xeris Pharmaceuticals, Inc. (XERS) Q4 2019 Earnings Call Transcript [The Motley Fool] -19.7%
9/10 Xeris Pharma halted pending news [Seeking Alpha] -11.8%
3/26 Xeris Pharmaceuticals Announces $0 Copay for Gvoke™ PFS for People With Diabetes -10.1%
2/11 Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock -9.4%
1/6 Xeris Pharma stock rallies more than 20% on study results [MarketWatch] -9.4%
11/7 Q3/2019 9/30/2019 EPS -1.220 ZacksConsensus -1.260 ActVsEst 0.040 - Beat -7.7%
4/10 Form 8-K XERIS PHARMACEUTICALS For: Apr 10 -7.1%
3/2 Form 4 XERIS PHARMACEUTICALS For: Jan 31 Filed by: Shannon John Patrick Jr -7.0%
4/30 Xeris Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020 -6.6%
3/11 Xeris Pharmaceuticals, Inc. (XERS) Q4 2019 Earnings Call Transcript [The Motley Fool] -19.7%
9/10 Xeris Pharma halted pending news [Seeking Alpha] -11.8%
3/26 Xeris Pharmaceuticals Announces $0 Copay for Gvoke™ PFS for People With Diabetes -10.1%
2/11 Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock -9.4%
1/6 Xeris Pharma stock rallies more than 20% on study results [MarketWatch] -9.4%
11/7 Q3/2019 9/30/2019 EPS -1.220 ZacksConsensus -1.260 ActVsEst 0.040 - Beat -7.7%
4/10 Form 8-K XERIS PHARMACEUTICALS For: Apr 10 -7.1%
3/2 Form 4 XERIS PHARMACEUTICALS For: Jan 31 Filed by: Shannon John Patrick Jr -7.0%
4/30 Xeris Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020 -6.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: